Cancer Center Information Systems is a Shared Resource providing Integrated Information systems In support of clinical and basic sdence biomedical research. The resource provides infrastructure, personnel, technical support, assistance and consultation In four areas - networks, databases, servers and web applications. The goal ofthe resource Is to provide comprehensive computational support to enable researchers to use technology In the most efficient manner possible to accomplish their research goals. Cancer Center Information Systems is direded by Robert P. Annechiarico, under the administrative supervision of Dr. Stephen L. George, Director of Blostatisfics. In addifion to Mr. Anriechiarico, CCIS has 19 full time staff positions. The resource provides database and applications development, web site support, server support and desktop support for 54 servers (virtual and stand-alone, more than doubling since the last renewal) and for over 1000 users. In addition to network server support, CCIS supports large scale servers and software, as well as high performance computational platforms, forthe Biostatistics Shared Resource and the Bioinformatics Shared Resource. This group supports the Informatics needs of a variety of research areas and programs. Support for the SPORES in Brain and Breast Cancer, the Cancer Genetics Network and the Protocol Office represent some ofthe larger efforts. CCIS is working closely with the Duke Health Technology Solufions, the Duke Translational Medicine Institute, and the Institute for Genome Sciences and Policy to integrate clinical data with research data. Support for the resource is provided through a combination of grant support, chargeback and institutional funding. At the national level, CCIS has been a leader in the development of software tools and standards within the caBIG program, contributing to several cornerstone applications and projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-40
Application #
8601852
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
40
Fiscal Year
2014
Total Cost
$213,311
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Xu, Yinghui; Wang, Yanru; Liu, Hongliang et al. (2018) Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog 57:22-31
Abdi, Khadar; Kuo, Chay T (2018) Laminating the mammalian cortex during development: cell polarity protein function and Hippo signaling. Genes Dev 32:740-741
Lu, Min; Sanderson, Sydney M; Zessin, Amelia et al. (2018) Exercise inhibits tumor growth and central carbon metabolism in patient-derived xenograft models of colorectal cancer. Cancer Metab 6:14
Qian, Danwen; Liu, Hongliang; Wang, Xiaomeng et al. (2018) Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer :
Ashcraft, Kathleen A; Choudhury, Kingshuk Roy; Birer, Sam R et al. (2018) Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion. Radiat Res 190:12-21
Ong, Cecilia T; Campbell, Brittany M; Thomas, Samantha M et al. (2018) Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. Ann Surg Oncol 25:2249-2260
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408

Showing the most recent 10 out of 513 publications